ReviewPharmaceutical medicine2025
Visionary Health Architects and Leaders: The Strategic Role of Medical Advisors in Modern Pharma.
Review in Pharmaceutical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper reviews the pivotal role of the Medical Advisor (MA) within the medical department of the pharmaceutical industry, highlighting their essential contribution to the development, commercialization, and appropriate use of medicines. In an environment characterised by stringent regulations and increasing demands for transparency, the MA role has become an indispensable position for ensuring optimal integration between scientific innovation and commercial strategy. The work of MAs facilitates cross-functional collaboration between a board spectrum of internal teams and external stakeholders, ensuring that scientific and clinical knowledge is effectively integrated at every stage of the product lifecycle. This includes leveraging emerging new technologies such as artificial intelligence and digital health solutions, as well as using machine learning to enhance predictive analytics. Such integration is critical to addressing unmet medical needs while aligning these initiatives with broader business objectives to drive innovation, market competitiveness, and patient outcomes. We explore the key responsibilities of today's MAs, which include contributing to the generation of data through clinical trials and post-authorization studies, providing continuing medical education, and communicating accurate information to diverse audiences, including healthcare providers, regulators, and patients. Furthermore, MAs promote innovation and therapeutic progress, acting as guardians of medical ethics. This review aims to provide a comprehensive understanding of the strategic role of MAs in bridging the gap between scientific research and clinical practice. Their contributions are critical to addressing current industry challenges, ensuring that companies remain competitive and making a significant contribution to patient wellbeing and medical progress.
Indexed as
Identifiers
40087202What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.